newsfilter
← Latest News
Business Wire·

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24